Clinical studies investigating the use of leuprorelin for prostate cancer in Asia
Background: Leuprorelin is a well-established treatment for prostate cancer (PCa); however, there is limited information on its use in Asian males. This review of English language publications between January 2000 and 2016 describes the outcomes of clinical trials on leuprorelin in Asian males with...
Main Authors: | Byung Ha Chung, Shigeo Horie, Edmund Chiong |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-03-01
|
Series: | Prostate International |
Online Access: | http://www.sciencedirect.com/science/article/pii/S228788821930025X |
Similar Items
-
The incidence, mortality, and risk factors of prostate cancer in Asian men
by: Byung Ha Chung, et al.
Published: (2019-03-01) -
Epidemiology of prostate cancer in Asia
by: Edmund Chiong
Published: (2015-12-01) -
Successful recovery from multiple organ failure associated with bicalutamide and leuprorelin acetate for prostate cancer
by: Seiichi Saito
Published: (2020-03-01) -
Editorial Comment to Castration‐resistant prostate cancer diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy
by: Maria Pennuto, et al.
Published: (2022-07-01) -
A Case of Paraphilia with Osteoporosis and Administered with Depot Leuprorelin
by: Dohee Kim, et al.
Published: (2019-10-01)